ÂÜÀòÂÒÂ×

Sadik Kassim currently serves as Chief Scientific Officer and Chief Technology Officer for Genomic Medicines at Danaher Corporation, where responsibilities include developing and implementing platform R&D strategies for genomic medicines. Simultaneously, Sadik Kassim advises the RA Capital ventures team on opportunities in the cell and gene therapy space. Previous experience includes roles as Chief Technology Officer at Vor Biopharma, Executive Director of Process Design at Kite Pharma, Chief Scientific Officer and Vice President at Mustang Bio, and Head of Early Analytical Development at Novartis. Additionally, Sadik Kassim has a significant research background from institutions like the National Institutes of Health, Johnson & Johnson, and the Gene Therapy Program at the University of Pennsylvania. Educational qualifications include a PhD in Microbiology and Immunology from Louisiana State University and a BS in Cell/Cellular and Molecular Biology from Tulane University.